Ketamine's Rapid Anti-Suicidal Effect Linked to Cortisol Spike in Study

A fast-acting treatment with a mysterious mechanism

Ketamine and its derivatives are among the most closely watched treatments in psychiatry because they do something conventional antidepressants rarely do: work in hours, not weeks. For a person experiencing suicidal thoughts, that speed can be lifesaving. But the rapid mechanism has been difficult to explain. New research is now pointing toward a surprising piece of the puzzle: morning cortisol, a hormone better known as a stress signal than as a mood stabilizer.

The study, presented by a team of psychiatric researchers, focused on patients undergoing ketamine treatment for depression and suicidal ideation. Among those who reported meaningful relief within a day, the researchers observed a distinct increase in morning cortisol. The hormonal boost remained detectable at least 24 hours after treatment. In contrast, patients who did not respond to ketamine showed no comparable cortisol rise. The association was tight enough that the researchers described the cortisol signal as a potential early marker of ketamine's anti-suicidal effect.

What the study found

The researchers measured cortisol levels using morning blood samples taken before and after ketamine administration. Cortisol naturally peaks shortly after waking, part of the body's circadian rhythm, so the team was careful to compare samples drawn under consistent conditions. The analysis focused on people with active suicidal thoughts, a group that is often excluded from traditional depression trials due to safety concerns. Despite that complexity, the team found a clear pattern: improvement in suicidal ideation tracked with an elevation in morning cortisol, and this specific hormonal boost persisted for at least 24 hours after treatment.

The study's authors stress that this does not prove ketamine relieves suicidal thoughts because of cortisol. It is possible, they argue, that the cortisol rise is a downstream effect of some deeper neural change, or that it serves as a marker of a stress system that has been acutely mobilized. But the timing is suggestive. Ketamine's psychiatric effects typically peak within 24 hours, and the cortisol response appears to follow a similar course. That overlap makes the hormone a plausible candidate for one of the biological bridges between ketamine and rapid clinical improvement.

Why morning cortisol matters

Cortisol is often discussed as the body's alarm system. It rises in the morning to help promote wakefulness; it spikes during stress; and it is heavily involved in metabolism, immune signaling, and memory formation. In depression, the cortisol system is frequently abnormal. Many patients show blunted cortisol awakening responses, flattened daily rhythms, or chronically elevated evening levels. These disruptions are thought to contribute to fatigue, poor concentration, and emotional dysregulation.

At first glance, a treatment that increases cortisol might seem counterproductive. But the new findings suggest the relevant change may not be the absolute level of cortisol so much as a short-term shift in the stress system's capacity to respond. Some researchers believe ketamine works by briefly mobilizing an adaptive stress response, pushing the brain into a state of heightened plasticity. Under that interpretation, a morning cortisol surge could be a sign that the stress system has been briefly "rebooted," allowing synapses and mood-regulating circuits to form new connections. That would help explain why a single dose of ketamine can produce effects that persist long after the drug has left the body.

A possible biomarker for urgent psychiatric care

One of the biggest challenges in treating suicidal patients is knowing quickly whether an intervention is working. Clinicians often rely on subjective reports, which can change hour to hour and may be influenced by sedation, hope, or fear. Suicidal ideation is also episodic, making it hard to distinguish a true drug response from spontaneous fluctuation. A biological marker measured in a simple blood test could therefore be extremely valuable.

The study raises the possibility that morning cortisol might fill that role. If the effect is reproducible, doctors could check cortisol 24 hours after a ketamine infusion to determine whether a patient is likely to benefit from a second dose. This would be particularly useful in emergency settings, where the next treatment decision often has to be made quickly. It could also help researchers design faster, more objective trials for new anti-suicidal medications, since cortisol response could be used as an early measure of drug activity.

But the authors are careful to note that cortisol is not a perfect biomarker. Levels vary naturally from person to person and are affected by sleep, food, stress, and time of awakening. A single morning sample would need to be standardized, and clinicians would need to account for individual variability. More work is needed to determine whether the cortisol signal predicts long-term outcome or only immediate relief.

Cautions and expert interpretation

Outside researchers who reviewed the findings said the study adds an important layer to ketamine research, though it leaves several questions open. One expressed caution about reading too much into a single hormone measurement. "Cortisol is a very broad signal," the researcher said. "It can rise for many reasons, including simply being in a different environment or sleeping better. What makes this interesting is the association with response, but association is not causality."

Another limitation is the size of the study. Ketamine trials involving patients with suicidal ideation are difficult to run, and participant numbers tend to be small. The current findings will need to be replicated in larger, more diverse groups that include people of different ages, genders, and medical histories. The researchers also did not test whether ketamine's cortisol effect occurs with non-ketamine treatments, so it remains unclear whether the marker is specific to ketamine or general to any effective anti-suicidal intervention.

What happens next

The research team says the next step is a prospective study in which cortisol samples are collected before and after treatment in a larger group, with longer follow-up. They also want to examine the relationship between morning cortisol and other markers of neuroplasticity, such as brain-derived neurotrophic factor, as well as measures of sleep and inflammation. Comparing different forms of ketamine, including IV infusions and intranasal esketamine, could reveal whether the cortisol response varies by route or dose.

If those studies confirm the link, cortisol testing could eventually be integrated into psychiatric practice as a companion to ketamine treatment. It might guide dose adjustments, help identify patients who are unlikely to respond, and provide a quantitative endpoint for clinicians working with a difficult and dangerous condition. Until then, the finding remains a promising clue rather than a proven answer.

The possibility that a hormone long associated with stress could help explain a drug's extraordinary anti-suicidal effect adds another twist to the ketamine story. It also underscores a broader theme in modern psychiatry: the same biological systems that help us meet threats may also, when briefly activated, help the brain heal.